Safety of Blood and Plasma Derivatives: Pathogen Reducing Technologies

Abstract

Human blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. Despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood transfusion. In this article various measures and technologies that can be applied in order to reduce the residual risk are reviewed.

Keywords

• Plasma Derivatives
• Virus Inactivation
• Blood Borne Viruses